Skip to main content
Premium Trial:

Request an Annual Quote

Patent for Editing

The Broad Institute was awarded a patent last week covering its engineered CRISPR-Cas9 system, a press release from the institute says.

According to US Patent No. 8,697,359, the "invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products." It also mentions how the tool could be used to treat a number of diseases.

“The CRISPR-Cas9 system is an extraordinary, powerful tool," Eric Lander, the director of the Broad, says in a statement. "The ability to edit a genome makes it possible to discover the biological mechanisms underlying human biology and, potentially, to treat certain human diseases."

The researcher listed on the patent is Feng Zhang, a core member of the Broad and co-founder of Editas Medicine, notes MIT's Technology Review.

Lander adds that the Broad will make the technology available to researchers around the world.

Still, Chelsea Loughran, an intellectual property litigation lawyer, tells Tech Review how this will affect people already using CRISPR is unclear. A Broad spokesperson echoed Lander's remark that the tool would be widely available, though said that specific licensing details weren't available.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.